Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Myeloablative Allogeneic Stem Cell Transplantation in CLL: A Single Centre Retrospective Study

Sonia Cerquozzi, MD FRCPC, Sunita Ghosh, PhD, P.Stat., Diana Quinlan, Amy Trottier, MD, Mary Lynn Savoie, MD FRCPC, Douglas A. Stewart, MD FRCPC, James A. Russell, MD FRCPC, Carolyn Owen, MD MDes (UK), FRCPC

Blood (2015) 126 (23): 5530.

https://doi.org/10.1182/blood.V126.23.5530.5530

Published: 2015

Journal Articles

Fludarabine Metabolite Level On Day Zero Does Not Affect Outcomes Of Hematopoietic Cell Transplantation In Patients With Normal Renal Function

Cameron D. Griffiths, MD, Ella S.M Ng, MSc., Bill Kangarloo, MSc., Tyler S Williamson, PhD, Reanne Booker, BSc, MSN, NP, Ping Yue, MD, Peter Duggan, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Christopher Brown, MD, Andrew Daly, MD, FRCPC, James A Russell, MD, Jan Storek, MD, PhD

Blood (2013) 122 (21): 2116.

https://doi.org/10.1182/blood.V122.21.2116.2116

Published: 2013

Journal Articles

Immune Reconstitution After Antithymocyte Globulin (ATG)-Conditioned Hematopoietic Cell Transplantation (HCT)

Mark Bosch, MD, FRCPC, Manveer Dhadda, Mette Hoegh-Petersen, MD, Yiping Liu, Laura M Hagel, Peter Podgorny, Alejandra Ugarte-Torres, MD, Joanne Luider, Iwona Auer-Grzesiak, MD, FRCPC, Adnan Mansoor, MD, FRCPC, James A Russell, Jan Storek, MD, PhD

Blood (2011) 118 (21): 1981.

https://doi.org/10.1182/blood.V118.21.1981.1981

Published: 2011

Journal Articles

Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) 0–1 Scores Predict Improved Outcome

Anthea Peters, MD, MSc, FRCPC, James A Russell, MD, Andrew Daly, MD, FRCPC, Nizar J Bahlis, MD, Michelle Geddes, MD, Peter Duggan, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 687.

https://doi.org/10.1182/blood.V116.21.687.687

Published: 2010

Journal Articles

High IL-15 Serum Levels on Day 7 After Hematopoietic Cell Transplantation Are Associated with a Low Likelihood of Graft-Vs-Host Disease and a High Likelihood of Infections

Laura M Hagel, Yiping Liu, Alejandra Ugarte-Torres, Tyler S Williamson, James A Russell, Jan Storek, MD, PhD

Blood (2010) 116 (21): 1271.

https://doi.org/10.1182/blood.V116.21.1271.1271

Published: 2010

Journal Articles

High Herpesvirus-Specific T Cell Counts Are Associated with near-Zero Likelihood of Malignancy Relapse and a Low Likelihood of Infections Due to Any pathogen.

Mette Hoegh-Petersen, MD, Sarah Sy, Alejandra Ugarte-Torres, Tyler S Williamson, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Yiping Liu, Stephanie Liu, Kevin Fonseca, Faisal Khan, James A Russell, Jan Storek, MD, PhD

Blood (2010) 116 (21): 1285.

https://doi.org/10.1182/blood.V116.21.1285.1285

Published: 2010

Journal Articles

Anti-GvHD Effect of Antithymocyte Globulin Is Mediated by Antibodies Binding to T Cells and Regulatory NK Cells, and Less So or Not at All by Antibodies Binding to Other Mononuclear Cell Subsets

Mette Hoegh-Petersen, MD, Minaa Amin, Yiping Liu, Alejandra Ugarte-Torres, Tyler S Williamson, Peter Podgorny, James A Russell, Jan Storek, MD, PhD

Blood (2010) 116 (21): 2346.

https://doi.org/10.1182/blood.V116.21.2346.2346

Published: 2010

Journal Articles

Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with a history of chronic graft-versus-host disease, and rare in nasal mucosa

Faisal M. Khan, Sarah Sy, Polly Louie, Alejandra Ugarte-Torres, Noureddine Berka, Gary D. Sinclair, Douglas A. Stewart, James A. Russell, Jan Storek

Blood (2010) 116 (10): 1803–1806.

https://doi.org/10.1182/blood-2009-10-249201

Published: 2010

Includes: Supplemental data

Journal Articles

CMV-Specific Immunity and CMV Complications in Seropositive HCT Recipients Depend On Donor Serostatus.

Alejandra Ugarte-Torres, MD, Yiping Liu, PhD, Tyler Williamson, Mette Hoegh-Petersen, MD, Diana Quinlan, RN, Lina Roa, Faisal Khan, PhD, James A. Russell, MD, Jan Storek, MD, PhD

Blood (2009) 114 (22): 2248.

https://doi.org/10.1182/blood.V114.22.2248.2248

Published: 2009

Journal Articles

FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.

Andrew Daly, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Ahsan Chaudhry, MD, Nizar J Bahlis, MD, FRCPC, Christopher Brown, MD, FRCPC, Peter Duggan, MD, FRCPC, Michelle Geddes, MD, FRCPC, Mary Lynn Savoie, MD, FRCPC, Jan Storek, MD, PhD, Maggie Yang, James A. Russell, MD, FRCPC

Blood (2009) 114 (22): 3384.

https://doi.org/10.1182/blood.V114.22.3384.3384

Published: 2009

Journal Articles

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation

Blood (2009) 113 (13): 3110–3118.

https://doi.org/10.1182/blood-2008-07-163212

Published: 2009

Includes: Supplemental data

Journal Articles

Genomic Instability Is Frequent in Oral and Rare in Nasal Mucosal Cells of Allogeneic HCT Recipients.

Faisal Khan, PhD, Sarah Sy, Polly Louie, Robyn Lee, Douglas A. Stewart, MD, FRCPC, James A. Russell, Jan Storek, MD, PhD

Blood (2008) 112 (11): 2140.

https://doi.org/10.1182/blood.V112.11.2140.2140

Published: 2008

Journal Articles

Epithelial Cells of Donor Origin after Allogeneic HCT: Result of Cell Fusion, Transdifferentiation (plasticity) or Transfer of Epithelial Cell Precursors with the Graft?

Faisal Khan, PhD, Sarah Sy, Polly Louie, Megan Smith, Judy Chernos, Robyn Lee, Noureddine Berka, Gary D. Sinclair, Richard Leigh, David Proud, James A. Russell, Jan Storek, MD, PhD

Blood (2008) 112 (11): 387.

https://doi.org/10.1182/blood.V112.11.387.387

Published: 2008

Journal Articles

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

James A. Russell, FRCP, Leanne Kmet, MSc, Mary Lynn Savoie, MD, Nizar J. Bahlis, MD, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, Michelle Geddes, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Christopher Brown, MD, Jan Storek, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 5398.

https://doi.org/10.1182/blood.V108.11.5398.5398

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

James A. Russell, FRCP, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, M. Ahsan Chaudhry, MD, A. Robert Turner, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, Christopher Brown, MD, Alexander Balogh, MD, Jan Storek, MD, Michelle Geddes, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3009.

https://doi.org/10.1182/blood.V108.11.3009.3009

Published: 2006

Journal Articles

Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.

Mary Lynn Savoie, MD, Alexander Balogh, MD, Ahsan Chaudhry, MD, Douglas A. Stewart, MD, Nizar J. Bahlis, MD, Jan Storek, MD,PhD, Christopher Brown, MD,PhD, Diana Quinlan, RN, Leanne Kmet, PhD, Loree M. Larratt, MD, A. Robert Turner, MD, James A. Russell, FRCPE

Blood (2006) 108 (11): 3010.

https://doi.org/10.1182/blood.V108.11.3010.3010

Published: 2006

Journal Articles

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Loree M. Larratt, MD, Michelle Geddes, MD, Jan Storek, MD, Mary Lynn Savoie, MD, Christopher Brown, MD, Nizar J. Bahlis, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3159.

https://doi.org/10.1182/blood.V108.11.3159.3159

Published: 2006

Journal Articles

High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.

Michelle Geddes, MD, Shahbal B. Kangarloo, PhD, Farrukh Naveed, BSc, Quinlan M. Diana, RN, Ahsan Chaudhry, MD, Mary Lynn Savoie, MD, Nizar J. Bahlis, MD, Douglas A. Stewart, MD, Christopher Brown, MD, PhD, Jan Storek, MD, PhD, Borje Andersson, MD, PhD, James A. Russell, MA, MB, B. Chir

Blood (2006) 108 (11): 313.

https://doi.org/10.1182/blood.V108.11.313.313

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Michelle Geddes, MD, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Alexander Balogh, MD, Jan Storek, MD, Christopher Brown, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3140.

https://doi.org/10.1182/blood.V108.11.3140.3140

Published: 2006

Journal Articles

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

James A. Russell, FRCP, Loree M. Larratt, MD, A. Robert Turner, MD, M. Ahsan Chaudhry, MD, Oluyeme Jeje, MD, Donald Morris, MD, Christopher Brown, MD, Diana M. Quinlan, BN, Douglas A. Stewart, MD

Blood (2006) 108 (11): 2865.

https://doi.org/10.1182/blood.V108.11.2865.2865

Published: 2006

NARROW

Myeloablative Allogeneic Stem Cell Transplantation in CLL: A Single Centre Retrospective Study

Fludarabine Metabolite Level On Day Zero Does Not Affect Outcomes Of Hematopoietic Cell Transplantation In Patients With Normal Renal Function

Immune Reconstitution After Antithymocyte Globulin (ATG)-Conditioned Hematopoietic Cell Transplantation (HCT)

Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) 0–1 Scores Predict Improved Outcome

High IL-15 Serum Levels on Day 7 After Hematopoietic Cell Transplantation Are Associated with a Low Likelihood of Graft-Vs-Host Disease and a High Likelihood of Infections

High Herpesvirus-Specific T Cell Counts Are Associated with near-Zero Likelihood of Malignancy Relapse and a Low Likelihood of Infections Due to Any pathogen.

Anti-GvHD Effect of Antithymocyte Globulin Is Mediated by Antibodies Binding to T Cells and Regulatory NK Cells, and Less So or Not at All by Antibodies Binding to Other Mononuclear Cell Subsets

Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with a history of chronic graft-versus-host disease, and rare in nasal mucosa

CMV-Specific Immunity and CMV Complications in Seropositive HCT Recipients Depend On Donor Serostatus.

FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.

The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation

Genomic Instability Is Frequent in Oral and Rare in Nasal Mucosal Cells of Allogeneic HCT Recipients.

Epithelial Cells of Donor Origin after Allogeneic HCT: Result of Cell Fusion, Transdifferentiation (plasticity) or Transfer of Epithelial Cell Precursors with the Graft?

Effect of Donor on Outcomes after Myeloablative Conditioning with Daily IV Busulfan and Fludarabine (FLUBUP) +/− TBI with Thymoglobulin: Transplants from Mismatched Unrelated Donors (MMUD) Have Worse Survival Due to Higher Transplant-Related Mortality (TRM).

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from Matched Related Donors (MRD) with a Myeloablative Once Daily IV Busulfan (Bu)/Fludarabine (Flu) Based Regimen (FLUBUP) with Thymoglobulin: Outcomes in 200 Patients with over One Year Follow-Up.

Total Body Irradiation (TBI) Added to Fludarabine/Busulfan/Antithymocyte Gobulin (FLUBUP/ATG) Conditioning Increases Overall Survival and Relapse-Free Survival in Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Stem Cell Transplants.

Transplant-Related Mortality in Patients ≥50 Years of Age Is No Lower after Transplantation from Young Fully Matched Unrelated Donors (MUD) Than from Matched Siblings When All Patients Are Given the FLUBUP Regimen with Thymoglobulin.

High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only